The length of survival of acute promyelocytic leukemia m3 is determined by a number of factors (e.g., severity of the disease, treatment effect, age, patient’s physical condition, complications, etc.), and the length of time varies. If the treatment effect is good, individual patients can achieve long-term survival.
Poor prognostic factors for acute promyelocytic leukemia m3 include giant spleen, advanced age, high white blood cell count, lower than normal platelet count, and chromosomal abnormalities, which can affect survival.
Specific therapeutic agents include all-trans retinoic acid, arsenious acid, cytarabine, and zorubicin.
Acute promyelocytic leukemia m3 is recommended to standardize the treatment under the guidance of specialists to reduce the adverse effects of the disease, many patients are likely to survive for a long time, and it is recommended that patients establish confidence in the treatment.